Work

652O Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC)

Year: 2023

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2023.09.1838

Authors: K.C. Arbour, S. Punekar, I. Garrido-Laguna, D.S. Hong, B. Wolpin, M.S. Pelster, M. Barve, A. Starodub, D. Sommerhalder, S. Chang, Y. Zhang, Z. Salman, X. Wang, C. Gustafson, A.I. Spira

Institutions: Memorial Sloan Kettering Cancer Center, NYU Langone Health, New York University, University of Utah, Huntsman Cancer Institute, The University of Texas MD Anderson Cancer Center, Dana-Farber Cancer Institute, Sarah Cannon, Mary Crowley Cancer Research Center, Christ Hospital, Revolution Medicines (United States), Virginia Cancer Specialists

Language: English

Topic: Protein Kinase Regulation and GTPase Signaling

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4387811516

FWCI: 9.638

Cites: 1

Cited by: 128

Related to: 10